Sounding The Alarm On The Future Of CNS Drug Development
This article was originally published in Pharmaceutical Approvals Monthly
The drug development paradigm for new central nervous system therapeutics is in need of a thorough reimagining, Tufts Center for the Study of Drug Development researchers assert in an analysis published in Scientific American.
You may also be interested in...
Tufts study indicates early talks with FDA could particularly help central nervous system product sponsors and their long clinical development programs.
The recent American Psychiatric Association annual meeting featured a lecture on drug development by Sanofi’s former head of CNS development Robert Lenox. In a post-meeting interview, he weighs in on the highs and lows of psychiatric drug development, as well as the newly released fifth edition of the Diagnostic and Statistical Manual of Mental Disorders.
Specialty Pharma Dominates Epilepsy Market, But Does It Have Resources To Develop Disease-Modifying Agents?
Upsher-Smith’s recent acquisition of research boutique Proximagen highlights the dynamics of the market: specialty pharma extending dominance and introducing new agents to the market, while most early R&D activity originates at small firms. But it may be difficult for this combination of players to bring forth the game-changing therapies that are needed, given the technical challenges of the disease space.